ii.Opnurasib(JDQ443): In vitro studies have revealed promising antitumor activity against KRAS G12C-mutant cancers with comutations that are responsible for acquired resistance to sotorasib and adagrasib monotherapy.221,227 The KontRASt-01 (NCT04699188) phase Ib/II, involving patients with KRAS mutations who had received standard chemotherapy and no prior KRAS inhibitors, had an ORR of 57%. The gene discussed is KRAS; the disease is cancer.